BlackRock
MLYS icon

BlackRock’s Mineralys Therapeutics MLYS Stock Holding History

BlackRock’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159M Buy
5,887,038
+1,405,456
+31% +$38.6M ﹤0.01% 1937
2026
Q1 		$121M Buy
4,481,582
+153,904
+4% +$4.51M ﹤0.01% 1982
2025
Q4 		$157M Buy
4,327,678
+656,064
+18% +$26.3M ﹤0.01% 1841
2025
Q3 		$139M Buy
3,671,614
+573,854
+19% +$12.4M ﹤0.01% 1893
2025
Q2 		$41.9M Buy
3,097,760
+647,733
+26% +$9.39M ﹤0.01% 2555
2025
Q1 		$38.9M Buy
2,450,027
+311,505
+15% +$3.58M ﹤0.01% 2515
2024
Q4 		$26.3M Sell
2,138,522
-5,646
-0.3% -$73.8K ﹤0.01% 2867
2024
Q3 		$26M Buy
2,144,168
+98,466
+5% +$1.19M ﹤0.01% 2868
2024
Q2 		$23.9M Buy
2,045,702
+702,139
+52% +$8.84M ﹤0.01% 2867
2024
Q1 		$17.3M Sell
1,343,563
-51,211
-4% -$632K ﹤0.01% 3067
2023
Q4 		$12M Buy
1,394,774
+499,725
+56% +$3.92M ﹤0.01% 3298
2023
Q3 		$8.51M Buy
895,049
+10,789
+1% +$141K ﹤0.01% 3431
2023
Q2 		$15.1M Buy
884,260
+134,571
+18% +$2.01M ﹤0.01% 3203
2023
Q1 		$11.7M Buy
+749,689
New +$12.6M ﹤0.01% 3234

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock's MLYS Position: Q2 2026 in Review

BlackRock increased its Mineralys Therapeutics (MLYS) stake by 31% in Q2 2026, buying an estimated $38.6M and bringing the position to 5,887,038 shares worth $159M. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

BlackRock first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • BlackRock held 5,887,038 shares of Mineralys Therapeutics worth $159M as of Q2 2026.
  • BlackRock bought 1,405,456 Mineralys Therapeutics shares in Q2 2026, an estimated $38.6M.
  • Mineralys Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1937 holding.
  • BlackRock first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.